Standard BioTools Inc. $LAB Shares Sold by MetLife Investment Management LLC

MetLife Investment Management LLC lowered its position in shares of Standard BioTools Inc. (NASDAQ:LAB) by 34.0% in the first quarter, according to the company in its most recent filing with the SEC. The firm owned 120,977 shares of the company’s stock after selling 62,405 shares during the quarter. MetLife Investment Management LLC’s holdings in Standard BioTools were worth $131,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Jump Financial LLC purchased a new stake in shares of Standard BioTools in the 1st quarter valued at $26,000. IQ EQ FUND MANAGEMENT IRELAND Ltd boosted its holdings in shares of Standard BioTools by 115.6% in the 1st quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 27,119 shares of the company’s stock valued at $29,000 after acquiring an additional 14,541 shares during the last quarter. CWM LLC boosted its holdings in shares of Standard BioTools by 101.8% in the 1st quarter. CWM LLC now owns 29,705 shares of the company’s stock valued at $32,000 after acquiring an additional 14,984 shares during the last quarter. Teacher Retirement System of Texas purchased a new stake in shares of Standard BioTools in the 1st quarter valued at $35,000. Finally, Impact Partnership Wealth LLC purchased a new stake in shares of Standard BioTools in the 1st quarter valued at $58,000. Institutional investors and hedge funds own 53.74% of the company’s stock.

Insider Activity at Standard BioTools

In other news, Director Casdin Partners Master Fund, L bought 250,000 shares of Standard BioTools stock in a transaction on Wednesday, September 3rd. The stock was acquired at an average price of $1.27 per share, with a total value of $317,500.00. Following the completion of the acquisition, the director directly owned 60,525,000 shares of the company’s stock, valued at $76,866,750. The trade was a 0.41% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders purchased a total of 1,133,220 shares of company stock worth $1,417,446 over the last ninety days. 23.16% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Wall Street Zen raised Standard BioTools from a “sell” rating to a “hold” rating in a report on Saturday, August 16th. Cowen cut Standard BioTools from a “buy” rating to a “hold” rating in a report on Wednesday, August 13th. Finally, TD Cowen cut Standard BioTools from a “buy” rating to a “hold” rating and set a $1.55 price objective for the company. in a report on Wednesday, August 13th. Three research analysts have rated the stock with a Hold rating, Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $1.55.

Standard BioTools Stock Performance

NASDAQ:LAB opened at $1.28 on Wednesday. The company has a fifty day moving average of $1.30 and a two-hundred day moving average of $1.18. The stock has a market capitalization of $488.95 million, a PE ratio of -4.00 and a beta of 1.29. Standard BioTools Inc. has a fifty-two week low of $0.92 and a fifty-two week high of $2.32.

Standard BioTools Company Profile

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.